A specific and sensitive assay for quantifying the immunosuppressant FK506 and its metabolites in blood and urine was developed.
FK506
(Fujisawa, Osaka, Japan) is considered a valuable and potent immunosuppressant after organ transplantation (1) and in the therapy of immunological diseases (2, 3). FK506 is isolated from Streptomyces tsukubaensis (4) and has a macrolide structure (CH69NO12) with a molecular mass of 803.5 Da (Figure 1) . In solution (CDC13), FK506 forms two rotamers in a ratio 2:1, the result of cis-trans isomerism of the C-N amide bonds. FK506 is soluble in alcohols, halogenated hydrocarbons, and ether. It is very sparingly soluble in aliphatic hydrocarbons and water. The molecule does not contain any chromophores, and its ultraviolet absorption maximum is 192 nm (5) (6) (7) .
FK506 is metabolized by the intestinal and liver cytochromeP-450 system to at least nine metabolites (8).
There is strong evidence that cytochrome P-450fflA4 is responsible for the FK506 metabolism (9). The reactions involved in FK506 metabolism are O-demethylation and hydroxylation. The metabolites formed retain biological activity. The immunosuppressive activity of the metabolites is 10% of that of FK506 (8, 10 
Fig. 1. Structure and metabolic pathways of FK506 and its metabolites
The carbon atomsare numberedaccording to Jones et at. (7) liver microsomes. No data concerning the in vivo metabolism of FK506 are available, because of the lack of a specific assay sensitive enough to allow quantification in body fluids or tissues of patients. The structure of FK506 and its metabolic pathways are displayed in Figure 1 .
Thus far, six different methods for quantifying FK506 have been described. The assay that was used to measure plasma concentrations of FK506 for clinical and pharmacokinetics studies (11-13) is an enzyme immunoassay, based on use of a monoclonal antibody (14) (15) (16) that probably is cross-reactive with the FK506 metabolites, according to clinical observations (17) . An automated whole-blood assay for the IMx analyzer ( in-vitro studies (8, 10 we used a Bruker 400-MHz nuclear magnetic resonance (NMR) spectrometer (Bruker, Karlsruhe, FRG).
MaterIals and Methods

Apparatus
Chemicals and Reagents
The analytical HPLC columns were filled with Nudeosil#{174} C8 (3-gm particles, 100-nm porewidth; Macherey Nagel, Duren, FRG 
CH(OAc)-CH(OCH3)
is part of the cyclohexyl residue; i.e., the acetylated hydroxy group is situated at C-32. Like FK506, the acetyl derivative occurs in the form of two rotational isomers in a ratio of 2:1, due to cis-trans isomerism of the C-N amide bond.
For use as internal standard, 10 L of the isolated fraction was injected into an analytical HPLC/UV system. FK506 and (or) the internal standard were eluted from the analytical columns (250 x 4 mm, C8, 3-gm particles) by a linear acetonitrile/water (pH 3.0) gradient: at time 0 mm, the mobile phase was 45% acetonitrile; at time 40 mm, it was 55% acetonitrile.
The flow rate was 0.7 mL/min, the oven temperature 75#{176}C, and the detection wavelength 205 nm. The internal standard was quantified by using the FK506 calibration curve. The concentration of the internal standard was adjusted with acetonitrile/water (75/25 by vol) to 1 j.g/L.
Extraction of FK506 and Its Metabolites
We tested Using the Chromsystems kit, we added 10 pL of the internal standard solution to 1 mL of blood or urine. We followed the extraction process described for cyclosporme and its metabolites as described in the kit manual.
The Chromsystems kit yielded
considerably cleaner extracts, with fewer substances interfering with the HPLC/UV assay of FK506 and the internal standard ( Figure 3 ). The absolute recoveries of 75-90% were not significantly different between the two extraction procedures. Therefore, we used the Chromsystems extraction procedure during the study.
Tests with the internal standard (32-O-acetyl-FK506), FK506, and an isolated metabolite blood samples showed peaks that interfered with FK506. This interfering material could be separated from FK506 and its metabolites by using a 100 x 4 mm C8 column and gradient elution (Figure 4) . In a first step, the gradient eluted the interfering material and then eluted the FK506 metabolites, FK506, and the internal standard.
HPLC/MS of
A complete chromatographic separation was not necessary, because the metabolites could be differentiated by their molecular ions. It was much more important to elute the compounds of interest at almost the same time because the sensitivity of the MS detection was dependent on the acetonitrile/water or methanol/water ratio of the mobile phase. The use of a gradient allowed us to elute FK506 and its metabolites from the columns at a composition of the mobile phase that yielded the greatest sensitivity during particle beam separation and MS analysis ( Figure 5 ). The sensitivity of the assay was best at a methanol/water volume ratio of 90/10. The limit of quantification in blood was 250 pg, determined by extraction of 1 mL of blood and injection of 150 pL of the extract. The intra-assay CV was 10.5% at 5 ng (n = 10). The imterassay CV was 12.3% at 1 .gfL, 11.3% at 5 p.g/L, and 13.2% at 50 g/L (all with n 10). The calibration curve after extraction of FK506 from blood had a correlation coefficient (r) of 0.998.
Analysis of extracts of human liver microsomal preparations after metabolism of 10 nmol of FK506 showed that all metabolites previously identified could be detected by HPLC/MS (Figure 6) . No other clinically relevant drugs were found to interfere with the assay.
Stability of the HPLC/MS system was tested by 50 Fig.4 . TiC, totalioncount 6 9 Ab.ord.n,. could be attributed to a time-dependent change of the shape of repeller in the MS source. Long-term stability could be evaluated by analysis of quality-control samples during a sequence of 75 extracted blood samples; the change of signal was 9.3% (n = 8), which is almost equal to the intra-assay CV described above. With the system described, as many as 75 samples could be run before the skimmers of the particle beam interface had to be cleaned or exchanged. The source of the MS had to be cleaned every 200-250 samples.
In blood samples, FK506 and a demethylated metabolite at 790 amu (demethyl-FK506), were found ( Figure  7) ; in urine, FK506 was found, as were metabolites at 776 (di-demethyl FK506), 790 (demethyl FK506), and 792 amu (di-demethyl hydroxyl FK506) (Figure 8 ).
DiscussIon
The HPLC/MS assay had several advantages over the other assays tested. The HPLC/UV assay was not sensitive enough. Most patients measured in this study had trough blood concentrations of FK506 in the range of 5-10 g/L, which was below the detection limit of the HPLCIIJV assay. For practical reasons, blood is much easier to handle, is reproducible, and is not subject to the erroneously high concentrations of FK506 seen in hemolyzed plasma. The problem of choice of matrix was exhaustively considered for the immunesuppressant cyclosporine as well; today, blood is the generally accepted matrix of choice (27, 28) In conclusion, HPLC/MS with a particle-beam interface allows the direct specific and sensitive quantification of FK506 and all its known metabolites within a 15-mm HPLC run, after simple solid-liquid extraction with a commercially available extraction kit.
